Trial Profile
A Phase 2 Study To Evaluate The Safety, Tolerability, Virologic And Immunologic Effect Of Single-Dose CP-675,206 In Patients Infected With Human Immunodeficiency Virus
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Tremelimumab (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Pfizer
- 03 Jun 2009 New trial record.